Continuous Renal Replacement Therapy (CRRT)LEVCRRTNCT07918833
Pharmacokinetics and Optimal Dosing of Levetiracetam in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy
An observational study of Continuous Renal Replacement Therapy (CRRT) and Pharmacokinetics, run by Chulalongkorn University at 1 site in Thailand.
Trial summary
Levetiracetam may be removed during continuous renal replacement therapy (CRRT), potentially affecting drug concentrations and seizure control. The optimal dosing regimen for critically ill patients receiving CRRT remains unclear. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Continuous Renal Replacement Therapy (CRRT), Pharmacokinetics, Levetiracetam
- What is being tested?
- Levetiracetam
- How many people
- 15 participants
- Where
- 1 siteThailand
- Study dates
- 30 Oct 2026to 30 Jun 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Critically ill adult patients aged 18 years or older admitted to ICUs who receive levetiracetam during CRRT. Eligible patients must have received CRRT for at least 24 hours and meet the study's inclusion and exclusion criteria.
Who may be able to join
- Adults aged 18 years or older.
- Patients admitted to any ICUs.
- Patients receiving CRRT for at least 24 hours.
- Hemodynamically stable patients, defined as having a SBP of at least 90 mmHg or a MAP of at least 60 mmHg, with the norepinephrine dose remaining stable or increasing by no more than 0.1 mcg/kg/min during the preceding 6 hours.
- Patients receiving intravenous or oral levetiracetam while receiving CRRT.
- Patients admitted to any ICUs.
- Patients receiving CRRT for at least 24 hours.
Who cannot join
- Pregnant patients
- Patients who are breastfeeding.
- Patients with a known hypersensitivity to levetiracetam or who develop a hypersensitivity reaction requiring discontinuation of levetiracetam during the study.
- Patients with cirrhosis classified as Child-Pugh-Turcotte class C.
- Patients receiving extracorporeal membrane oxygenation (ECMO).
- Patients who, or whose legally authorized representatives, do not provide informed consent for study participation.
- Patients with an expected survival of less than 24 hours, as assessed by the attending physician.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Thailand1 site
King Chulalongkorn Memorial Hospital
Pathum Wan, Bangkok, 10330
Supanat Khueankaew, PharmD, +6622188403, supanat.khnat@gmail.com
Weerachai Chaijamorn, BSc(Pharm), BCP, FACP, BCPS, +6622188403, weerachai.c@chula.ac.th
About this study
Levetiracetam may be removed during continuous renal replacement therapy (CRRT), potentially affecting drug concentrations and seizure control. The optimal dosing regimen for critically ill patients receiving CRRT remains unclear. This observational study will investigate the pharmacokinetics of levetiracetam in critically ill adult patients receiving CRRT. Blood, CRRT effluent, and urine samples will be collected throughout one dosing interval to measure levetiracetam concentrations. The data will be used to develop a population pharmacokinetic model and perform pharmacokinetic/pharmacodynamic modeling and Monte Carlo simulations to evaluate dosing regimens and estimate the probability of achieving predefined drug concentration or exposure targets. The findings may help identify an appropriate levetiracetam dosing regimen for critically ill patients receiving CRRT.
- Being tested
- Levetiracetam
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
LevetiracetamDrug
Levetiracetam administered as part of routine clinical care to critically ill adult patients receiving CRRT. The dose, dosing interval, and route of administration are determined by the treating physician. CRRT is prescribed and managed by the treating clinical team (nephrologist) as part of routine clinical care. The investigators do not assign or modify levetiracetam treatment or CRRT prescriptions for research purposes. Levetiracetam concentrations are measured in blood, CRRT effluent, and urine samples collected at protocol-specified time points to characterize its pharmacokinetic profile during CRRT.
| Study group | Role | What they receive |
|---|---|---|
| Critically Ill Adult Patients Receiving Levetiracetam During CRRT | Critically ill adult patients aged 18 years or older admitted to ICUs who receive levetiracetam during CRRT. Eligible participants must have received CRRT for at least 24 hours and meet the study's inclusion and exclusion criteria. Receives: Drug: Levetiracetam |
What is being measured
The primary outcome is the main question the study is designed to answer.
Probability of target attainment for simulated levetiracetam dosing regimens
Monte Carlo simulations based on the developed population pharmacokinetic model will be used to estimate the probability of target attainment (PTA) for each simulated levetiracetam dosing regimen. Target attainment will be evaluated according to the prespecified therapeutic concentration and AUC target criteria in the study protocol. Results will be reported as the probability or percentage of simulated patients achieving the target for each dosing regimen.
Measured: At completion of population pharmacokinetic model development and Monte Carlo simulations (approximately 23 months after study start).
Secondary outcomes (10)
Levetiracetam plasma exposure based on the area under the concentration-time curve (AUC)
Levetiracetam AUC will be estimated using noncompartmental analysis of concentration-time data collected over a single dosing interval. Simultaneous samples will be collected from the pre-filter, post-filter, and effluent ports before dosing and at 7 prespecified time points after intravenous or oral administration.
Measured: From predose (0 hours) to pre-next dose (e.g., 12 hours) after initiation of levetiracetam administration.
Volume of distribution of levetiracetam
The volume of distribution of levetiracetam will be estimated using noncompartmental pharmacokinetic analysis based on the administered dose, elimination rate constant, and AUC.
Measured: From predose (0 hours) to pre-next dose (e.g., 12 hours) after initiation of levetiracetam administration.
Total clearance of levetiracetam
Total clearance of levetiracetam will be estimated using noncompartmental pharmacokinetic analysis based on the administered dose and AUC.
Measured: From predose (0 hours) to pre-next dose (e.g., 12 hours) after initiation of levetiracetam administration.
Levetiracetam sieving and saturation coefficients during continuous renal replacement therapy (CRRT)
The sieving coefficient (SC) and saturation coefficient (SA) of levetiracetam will be determined using pre-filter, post-filter, and effluent concentrations to evaluate drug transfer across the CRRT filter under different CRRT modalities, including continuous venovenous hemofiltration (CVVH), continuous venovenous hemodialysis (CVVHD), and continuous venovenous hemodiafiltration (CVVHDF).
Measured: From predose (0 hours) to pre-next dose (e.g., 12 hours) after initiation of levetiracetam administration.
Levetiracetam clearance by CRRT
Levetiracetam clearance by CRRT will be calculated based on pre-filter, post-filter, and effluent concentrations, together with replacement or dialysate flow rates according to the CRRT modality and dilution method, including CVVH, CVVHD, and CVVHDF.
Measured: From predose (0 hours) to pre-next dose (e.g., 12 hours) after initiation of levetiracetam administration.
Renal clearance of levetiracetam
Renal clearance of levetiracetam will be calculated based on urinary levetiracetam concentrations, urine volume, and plasma levetiracetam concentrations.
Measured: From predose (0 hours) to pre-next dose (e.g., 12 hours) after initiation of levetiracetam administration.
Non-renal clearance of levetiracetam
Non-renal clearance of levetiracetam will be estimated from total systemic drug clearance after accounting for renal and CRRT clearance.
Measured: From predose (0 hours) to pre-next dose (e.g., 12 hours) after initiation of levetiracetam administration.
Population typical value of levetiracetam clearance
The typical population value of levetiracetam clearance will be estimated using nonlinear mixed-effects modeling based on pre-filter and post-filter plasma concentration data collected from critically ill patients receiving CRRT.
Measured: Following completion of pharmacokinetic data collection and population pharmacokinetic analysis (approximately 23 months after study start).
Population typical value of levetiracetam volume of distribution
The typical population value of levetiracetam volume of distribution will be estimated using nonlinear mixed-effects modeling based on pre-filter and post-filter plasma concentration data collected from critically ill patients receiving CRRT.
Measured: Following completion of pharmacokinetic data collection and population pharmacokinetic analysis (approximately 23 months after study start).
Population typical value of CRRT-mediated levetiracetam clearance
The typical population value of CRRT-mediated levetiracetam clearance will be estimated using levetiracetam concentrations in plasma and effluent fluid, together with effluent flow rate, in critically ill patients receiving CRRT.
Measured: Following completion of pharmacokinetic data collection and population pharmacokinetic analysis (approximately 23 months after study start).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Nov 2026
- Study start30 Oct 2026 (estimated)
- Primary completion30 Sep 2027 (estimated)
- Study completion30 Jun 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (9)Papers the sponsor has linked to this study.
- Other trials for Continuous Renal Replacement Therapy (CRRT)Studies of the same condition, open and under way.
- More trials run by Chulalongkorn UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 15 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Chulalongkorn University
- Sponsor type
- University, hospital or other
- Collaborators
- Ratchadapiseksompotch Fund
- Responsible party
- Principal investigator, Supanat Khueankaew, PharmD, Chulalongkorn University
- Investigators
- Weerachai Chaijamorn, BSc (Pharm), BCP, FACP, BCPS, Study director, Associate Professor, Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07918833
- Sponsor's protocol ID
- 0551/2026
- Acronym
- LEVCRRT
- Status last verified
- Oct 2026
- First submitted
- 14 Oct 2026
- Last updated
- 5 Nov 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: The study team does not currently plan to share IPD with other researchers due to concerns regarding patient confidentiality, participant privacy, and the potential risk of re-identification. Access to study data will be restricted to researchers in the Pharmacometrics for Health Sciences Research Group, Faculty of Pharmaceutical Sciences, Chulalongkorn University, and individuals authorized in writing by the researchers. Any future proposal to share IPD will be reviewed for consistency with the informed consent, ethics committee requirements, institutional policies, and applicable laws.
Publications
Chaijamorn W, Charoensareerat T, Rungkitwattanakul D, Phunpon S, Sathienluckana T, Srisawat N, Pattharachayakul S. Levetiracetam dosing in patients receiving continuous renal replacement therapy. Epilepsia. 2021 Sep;62(9):2151-2158. doi: 10.1111/epi.16971. Epub 2021 Jul 11.
PubMed 34247386Chappell K, Kimmons LA, Haller JT, Canada RB, He H, Hudson JQ. Levetiracetam pharmacokinetics in critically ill patients undergoing renal replacement therapy. J Crit Care. 2021 Feb;61:216-220. doi: 10.1016/j.jcrc.2020.10.032. Epub 2020 Nov 2.
PubMed 33217623Kalaria SN, Armahizer M, McCarthy P, Badjatia N, Gobburu JV, Gopalakrishnan M. A Practice-Based, Clinical Pharmacokinetic Study to Inform Levetiracetam Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemofiltration (PADRE-01). Clin Transl Sci. 2020 Sep;13(5):950-959. doi: 10.1111/cts.12782. Epub 2020 Apr 3.
PubMed 32223067Louie JM, Raphael KL, Barker B. Levetiracetam Use With Continuous Renal Replacement Therapy. Ann Pharmacother. 2015 Sep;49(9):1079-80. doi: 10.1177/1060028015591845. Epub 2015 Jun 23. No abstract available.
PubMed 26104053Van Matre ET, Mueller SW, Fish DN, MacLaren R, Cava LF, Neumann RT, Kiser TH. Levetiracetam Pharmacokinetics in a Patient with Intracranial Hemorrhage Undergoing Continuous Veno-Venous Hemofiltration. Am J Case Rep. 2017 Apr 27;18:458-462. doi: 10.12659/ajcr.902709.
PubMed 28446744Nei SD, Wittwer ED, Kashani KB, Frazee EN. Levetiracetam Pharmacokinetics in a Patient Receiving Continuous Venovenous Hemofiltration and Venoarterial Extracorporeal Membrane Oxygenation. Pharmacotherapy. 2015 Aug;35(8):e127-30. doi: 10.1002/phar.1615. Epub 2015 Aug 3.
PubMed 26242293New AM, Nei SD, Kashani KB, Rabinstein AA, Frazee EN. Levetiracetam Pharmacokinetics During Continuous Venovenous Hemofiltration and Acute Liver Dysfunction. Neurocrit Care. 2016 Aug;25(1):141-4. doi: 10.1007/s12028-016-0242-1.
PubMed 26800696le Noble JL, Foudraine NA, Kornips FH, van Dam DG, Neef C, Janssen PK. Extracorporeal Clearance of Levetiracetam During Continuous Venovenous Hemofiltration in a Critically Ill Patient and New Dosing Recommendation. J Clin Pharmacol. 2017 Apr;57(4):536-537. doi: 10.1002/jcph.844. Epub 2016 Nov 21. No abstract available.
PubMed 27868207Brockmoller J, Thomsen T, Wittstock M, Coupez R, Lochs H, Roots I. Pharmacokinetics of levetiracetam in patients with moderate to severe liver cirrhosis (Child-Pugh classes A, B, and C): characterization by dynamic liver function tests. Clin Pharmacol Ther. 2005 Jun;77(6):529-41. doi: 10.1016/j.clpt.2005.02.003.
PubMed 15961984
Study at a glance
From the registry record, last updated by the sponsor on 5 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pharmacokinetics and Optimal Dosing of Levetiracetam in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy
- ClinicalTrials.gov ID
- NCT07918833
- Acronym / sponsor ID
- LEVCRRT / 0551/2026
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 15 participants (estimated)
- Lead sponsor
- Chulalongkorn UniversityUniversity, hospital or other
- Collaborators
- Ratchadapiseksompotch Fund
- Study start
- 30 Oct 2026 (estimated)
- Primary completion
- 30 Sep 2027 (estimated)
- Study completion
- 30 Jun 2028 (estimated)
- First posted
- 5 Nov 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Levetiracetam may be removed during continuous renal replacement therapy (CRRT), potentially affecting drug concentrations and seizure control. The optimal dosing regimen for critically ill patients receiving CRRT remains unclear. This observational study will investigate the pharmacokinetics of levetiracetam in critically ill adult patients receiving CRRT. Blood, CRRT effluent, and urine samples will be collected throughout one dosing interval to measure levetiracetam concentrations. The data will be used to develop a population pharmacokinetic model and perform pharmacokinetic/pharmacodynamic modeling and Monte Carlo simulations to evaluate dosing regimens and estimate the probability of achieving predefined drug concentration or exposure targets. The findings may help identify an appropriate levetiracetam dosing regimen for critically ill patients receiving CRRT.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Critically Ill Adult Patients Receiving Levetiracetam During CRRT | – | Drug: LevetiracetamCritically ill adult patients aged 18 years or older admitted to ICUs who receive levetiracetam during CRRT. Eligible participants must have received CRRT for at least 24 hours and meet the study's inclusion and exclusion criteria. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Critically ill adult patients aged 18 years or older admitted to ICUs who receive levetiracetam during CRRT. Eligible patients must have received CRRT for at least 24 hours and meet the study's inclusion and exclusion criteria.
Key inclusion criteria (7 listed)
- Adults aged 18 years or older.
- Patients admitted to any ICUs.
- Patients receiving CRRT for at least 24 hours.
- Hemodynamically stable patients, defined as having a SBP of at least 90 mmHg or a MAP of at least 60 mmHg, with the norepinephrine dose remaining stable or increasing by no more than 0.1 mcg/kg/min during the preceding 6 hours.
- Patients receiving intravenous or oral levetiracetam while receiving CRRT.
Key exclusion criteria (7 listed)
- Pregnant patients
- Patients who are breastfeeding.
- Patients with a known hypersensitivity to levetiracetam or who develop a hypersensitivity reaction requiring discontinuation of levetiracetam during the study.
- Patients with cirrhosis classified as Child-Pugh-Turcotte class C.
- Patients receiving extracorporeal membrane oxygenation (ECMO).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| LevetiracetamLevetiracetam administered as part of routine clinical care to critically ill adult patients receiving CRRT. The dose, dosing interval, and route of administration are determined by the treating physician. CRRT is prescribed and managed by the treating clinical team (nephrologist) as part of routine clinical care. The investigators do not assign or modify levetiracetam treatment or CRRT prescriptions for research purposes. Levetiracetam concentrations are measured in blood, CRRT effluent, and urine samples collected at protocol-specified time points to characterize its pharmacokinetic profile during CRRT. | Drug | Critically Ill Adult Patients Receiving Levetiracetam During CRRT |
Primary outcome
Probability of target attainment for simulated levetiracetam dosing regimens
Time frame: At completion of population pharmacokinetic model development and Monte Carlo simulations (approximately 23 months after study start).
Monte Carlo simulations based on the developed population pharmacokinetic model will be used to estimate the probability of target attainment (PTA) for each simulated levetiracetam dosing regimen. Target attainment will be evaluated according to the prespecified therapeutic concentration and AUC target criteria in the study protocol. Results will be reported as the probability or percentage of simulated patients achieving the target for each dosing regimen.
10 secondary outcomes
Levetiracetam plasma exposure based on the area under the concentration-time curve (AUC)
Time frame: From predose (0 hours) to pre-next dose (e.g., 12 hours) after initiation of levetiracetam administration.
Volume of distribution of levetiracetam
Time frame: From predose (0 hours) to pre-next dose (e.g., 12 hours) after initiation of levetiracetam administration.
Total clearance of levetiracetam
Time frame: From predose (0 hours) to pre-next dose (e.g., 12 hours) after initiation of levetiracetam administration.
Levetiracetam sieving and saturation coefficients during continuous renal replacement therapy (CRRT)
Time frame: From predose (0 hours) to pre-next dose (e.g., 12 hours) after initiation of levetiracetam administration.
Levetiracetam clearance by CRRT
Time frame: From predose (0 hours) to pre-next dose (e.g., 12 hours) after initiation of levetiracetam administration.
Renal clearance of levetiracetam
Time frame: From predose (0 hours) to pre-next dose (e.g., 12 hours) after initiation of levetiracetam administration.
Non-renal clearance of levetiracetam
Time frame: From predose (0 hours) to pre-next dose (e.g., 12 hours) after initiation of levetiracetam administration.
Population typical value of levetiracetam clearance
Time frame: Following completion of pharmacokinetic data collection and population pharmacokinetic analysis (approximately 23 months after study start).
Population typical value of levetiracetam volume of distribution
Time frame: Following completion of pharmacokinetic data collection and population pharmacokinetic analysis (approximately 23 months after study start).
Population typical value of CRRT-mediated levetiracetam clearance
Time frame: Following completion of pharmacokinetic data collection and population pharmacokinetic analysis (approximately 23 months after study start).
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Nov 2026.
- Background: PubMed 34247386Chaijamorn W, Charoensareerat T, Rungkitwattanakul D, Phunpon S, Sathienluckana T, Srisawat N, Pattharachayakul S. Levetiracetam dosing in patients receiving continuous renal replacement therapy. Epilepsia. 2021 Sep;62(9):2151-2158. doi: 10.1111/epi.16971. Epub 2021 Jul 11.
- Background: PubMed 33217623Chappell K, Kimmons LA, Haller JT, Canada RB, He H, Hudson JQ. Levetiracetam pharmacokinetics in critically ill patients undergoing renal replacement therapy. J Crit Care. 2021 Feb;61:216-220. doi: 10.1016/j.jcrc.2020.10.032. Epub 2020 Nov 2.
- Background: PubMed 32223067Kalaria SN, Armahizer M, McCarthy P, Badjatia N, Gobburu JV, Gopalakrishnan M. A Practice-Based, Clinical Pharmacokinetic Study to Inform Levetiracetam Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemofiltration (PADRE-01). Clin Transl Sci. 2020 Sep;13(5):950-959. doi: 10.1111/cts.12782. Epub 2020 Apr 3.
- Background: PubMed 26104053Louie JM, Raphael KL, Barker B. Levetiracetam Use With Continuous Renal Replacement Therapy. Ann Pharmacother. 2015 Sep;49(9):1079-80. doi: 10.1177/1060028015591845. Epub 2015 Jun 23. No abstract available.
- Background: PubMed 28446744Van Matre ET, Mueller SW, Fish DN, MacLaren R, Cava LF, Neumann RT, Kiser TH. Levetiracetam Pharmacokinetics in a Patient with Intracranial Hemorrhage Undergoing Continuous Veno-Venous Hemofiltration. Am J Case Rep. 2017 Apr 27;18:458-462. doi: 10.12659/ajcr.902709.
- Background: PubMed 26242293Nei SD, Wittwer ED, Kashani KB, Frazee EN. Levetiracetam Pharmacokinetics in a Patient Receiving Continuous Venovenous Hemofiltration and Venoarterial Extracorporeal Membrane Oxygenation. Pharmacotherapy. 2015 Aug;35(8):e127-30. doi: 10.1002/phar.1615. Epub 2015 Aug 3.
- Background: PubMed 26800696New AM, Nei SD, Kashani KB, Rabinstein AA, Frazee EN. Levetiracetam Pharmacokinetics During Continuous Venovenous Hemofiltration and Acute Liver Dysfunction. Neurocrit Care. 2016 Aug;25(1):141-4. doi: 10.1007/s12028-016-0242-1.
- Background: PubMed 27868207le Noble JL, Foudraine NA, Kornips FH, van Dam DG, Neef C, Janssen PK. Extracorporeal Clearance of Levetiracetam During Continuous Venovenous Hemofiltration in a Critically Ill Patient and New Dosing Recommendation. J Clin Pharmacol. 2017 Apr;57(4):536-537. doi: 10.1002/jcph.844. Epub 2016 Nov 21. No abstract available.
- Background: PubMed 15961984Brockmoller J, Thomsen T, Wittstock M, Coupez R, Lochs H, Roots I. Pharmacokinetics of levetiracetam in patients with moderate to severe liver cirrhosis (Child-Pugh classes A, B, and C): characterization by dynamic liver function tests. Clin Pharmacol Ther. 2005 Jun;77(6):529-41. doi: 10.1016/j.clpt.2005.02.003.
- Individual participant dataSharing planned: No. The study team does not currently plan to share IPD with other researchers due to concerns regarding patient confidentiality, participant privacy, and the potential risk of re-identification. Access to study data will be restricted to researchers in the Pharmacometrics for Health Sciences Research Group, Faculty of Pharmaceutical Sciences, Chulalongkorn University, and individuals authorized in writing by the researchers. Any future proposal to share IPD will be reviewed for consistency with the informed consent, ethics committee requirements, institutional policies, and applicable laws.
Related trials for Continuous Renal Replacement Therapy (CRRT)
Not yet recruitingObservational study
Diastolic Shock Index for Predicting Hemodynamic Instability During Continuous Renal Replacement Therapy
Acute Kidney Injury, Hypotension (MeSH: D007022)
Not yet recruitingObservational study
Magnesium Kinetics During Citrate-Anticoagulated CRRT
Continuous Renal Replacement Therapy (CRRT), Magnesium
RecruitingPhase 4
Effect of a Furosemide Stress Test-Guided Strategy on Liberation From Continuous Renal Replacement Therapy in Critically Ill Patients With Acute Kidney Injury
Acute Kidney Injury
Not yet recruitingObservational study
Effect of Filter Lifespan in CRRT on New Infections in Critically Ill Patients With AKI
Acute Kidney Injury
Recruiting
Effect of High Versus Standard Protein Intake in Critically Ill Patients With Acute Kidney Injury Requiring Continuous Renal Replacement Therapy
Acute Kidney Failure Stage 3, Continuous Renal Replacement Therapy (CRRT)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Weerachai Chaijamorn, BSc (Pharm), BCP, FACP, BCPS study director
Associate Professor, Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Continuous Renal Replacement Therapy (CRRT) and Pharmacokinetics, run by Chulalongkorn University at 1 site in Thailand.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 5 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Thailand. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Supanat Khueankaew, PharmD (+6622188403, supanat.khnat@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Probability of target attainment for simulated levetiracetam dosing regimens (time frame: At completion of population pharmacokinetic model development and Monte Carlo simulations (approximately 23 months after study start).). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07918833, which also lists 9 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Nov 2026.